In this case, a patient diagnosed with psoriatic arthritis, who was under adalimumab treatment, has been prescribed tenofovir (Vemlidy®) at a dosage of 300 mg once daily since the initiation of anti-TNFα biologics. Here, TNF is linked to psoriatic arthritis.